Literature DB >> 17295659

Potential physiological and pathophysiological roles for protease-activated receptor-2 in the kidney.

David A Vesey1, John D Hooper, Glenda C Gobe, David W Johnson.   

Abstract

The protease-activated receptor-2 (PAR-2), the second of four members of a unique subfamily of G-protein coupled receptors, is abundantly expressed in the kidney. In a similar manner to other PAR cleavage of its extracellular N-terminus exposes a tethered ligand, SLIGKV in humans, which acts as an intramolecular ligand to activate itself. In the kidney, PAR-2 expression has been variably reported in collecting duct cells, mesangial cells, interstitial fibroblasts, vascular endothelial cells, vascular smooth muscle cells and proximal tubular cells. Despite this renal expression data, the function of PAR-2 in the kidney remains unknown. More than 15 different mammalian serine proteases have been shown to activate PAR-2 in an in vitro setting, but it is still unclear which of these are physiologically relevant activators of PAR-2 in specific tissues. Their identification could provide novel therapeutic targets. PAR-2 activates a number of down-stream signalling molecules that include protein kinase C, extracellular signal regulated kinase and nuclear factor kappa-B. Proteases that can activate PAR-2 are generated and released from cells during injury, inflammation and malignancy and can thus signal to cells under these conditions. Potential physiological and pathophysiological roles for PAR-2 in the kidney include the regulation of inflammation, blood flow, and ion transport and tissue protection, repair and fibrosis. In this review the potential roles of PAR-2 in the kidney are highlighted and discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17295659     DOI: 10.1111/j.1440-1797.2006.00746.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  8 in total

1.  Cathepsin S-Dependent Protease-Activated Receptor-2 Activation: A New Mechanism of Endothelial Dysfunction.

Authors:  David J Nikolic-Paterson
Journal:  J Am Soc Nephrol       Date:  2015-11-20       Impact factor: 10.121

Review 2.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

3.  Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110).

Authors:  J Y Suen; G D Barry; R J Lohman; M A Halili; A J Cotterell; G T Le; D P Fairlie
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells.

Authors:  Jacky Y Suen; Brooke Gardiner; Sean Grimmond; David P Fairlie
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

5.  Expression of protease activated receptor-2 is reduced in renal cell carcinoma biopsies and cell lines.

Authors:  Christudas Morais; Retnagowri Rajandram; Jade S Blakeney; Abishek Iyer; Jacky Y Suen; David W Johnson; Glenda C Gobe; David P Fairlie; David A Vesey
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

6.  Exploring the pathogenesis of diabetic kidney disease by microarray data analysis.

Authors:  Haiyan Cao; Xiaosheng Rao; Junya Jia; Tiekun Yan; Dong Li
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

Review 7.  Innate immunity in diabetic kidney disease.

Authors:  Sydney C W Tang; Wai Han Yiu
Journal:  Nat Rev Nephrol       Date:  2020-01-15       Impact factor: 28.314

8.  Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2.

Authors:  Yohan Seo; Chin Hee Mun; So-Hyeon Park; Dongkyu Jeon; Su Jeong Kim; Taejun Yoon; Eunhee Ko; Sungwoo Jo; Yong-Beom Park; Wan Namkung; Sang-Won Lee
Journal:  Int J Mol Sci       Date:  2020-07-14       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.